The family Filoviridae contains three genera, Ebolavirus, Marburgvirus, and Cuevavirus 1 . Some members of the genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in over 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid-acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primates against ZEBOV 2 . In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further-attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and both provided complete, single-dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.
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Since discovery of the virus in 1976, outbreaks of ZEBOV have been detected sporadically in Africa. With increasing population growth the frequency of human contact with natural virus reservoirs 3 is likely to rise, potentially leading to more catastrophic outbreaks such as the current epidemic in West Africa, thus increasing the need for effective antiviral strategies. A highly effective countermeasure would be a preventive vaccine that can be simply and widely administered to people in regions of virus zoonosis and provide a 'blanket immunity' curtailing any future outbreaks. Also important will be the ability to rapidly combat deliberate misuse of these deadly viruses. Therefore, a preventive vaccine should ideally confer rapid, single-dose protection.
There are currently no licensed filovirus vaccines or post-exposure treatments available for human use. However, there are at least ten different vaccine approaches that have shown the potential to protect nonhuman primates (NHPs) from lethal ZEBOV infection, including platforms based on recombinant adenovirus serotype 5 (rAd5) vectors, combined DNA/rAd5 vectors, combined rAd serotype 26 and 35 vectors, recombinant chimpanzee adenovirus serotype 3 (rChAd3) vectors, combined rChAd3 and modified vaccinia Ankara (MVA) vectors, virus-like particles (VLPs), alphavirus replicons, recombinant human parainfluenza virus 3 (rHPIV3), rabies virus, and recombinant vesicular stomatitis virus (rVSV) 2 . Of the vaccines advancing to phase I trials, the rChAd3 and rVSV vectored vaccines have shown success in singledose protection of NHPs against ZEBOV challenge; with the caveat that the rChAd3/ZEBOV vaccine requires a boost with an MVA/ ZEBOV vector for protection past 6 months 4 . Also, NHPs inocu-lated with the rChAd3/ZEBOV vaccine were challenged with a ZEBOV seed stock containing a large virus population encoding 8 uridines (U) at a critical transcription editing site in the GP gene 4 . This specific genetic feature typically arises following prolonged passage of ZEBOV in Vero E6 cells and results in higher levels of expression of full-length GP. In contrast, low-passage ZEBOV isolates retain 7U at the GP editing site, resulting in higher levels of secreted GP (sGP) expression, which is associated with greater viral virulence [5] [6] [7] . Importantly, studies have shown that rAd-based ZEBOV vaccines that completely protect NHPs against ZEBOV stocks containing high populations of 8U virus are not able to completely protect vaccinated macaques challenged with ZEBOV stocks containing high populations of 7U virus 8 .
The first generation rVSV/ZEBOV vaccine that replaces the VSV glycoprotein G with the ZEBOV GP (rVSV/ZEBOVDG), originally developed by Drs Feldmann and Geisbert 9 and currently licensed by Merck, has demonstrated solid single-dose NHP protection against a low-passage 7U ZEBOV stock 8 . The rVSV/ZEBOVDG vector has also protected 50% of NHPs when administered shortly after ZEBOV challenge 10 , and has demonstrated safety in a NHP neurovirulence model 11 . However, there is a robust post-vaccination viraemia in macaques and a recent phase I trial of the rVSV/ZEBOVDG vaccine in Geneva was halted due to temporary joint pain in some patients. The level of vaccine-associated viraemia and frequency of adverse events will be more fully documented as data from ongoing phase 3 trials become available for this vector; but the early observation suggest that a further-attenuated rVSV vector may be more desirable for widespread administration in endemic regions of Africa.
To address this possible safety concern we have developed and tested two further-attenuated rVSV/ZEBOV vaccine candidates for efficacy. One of these vaccines is based on an rVSV vector that has advanced through clinical evaluation. It was attenuated by translocating the VSV nucleoprotein (N) gene from position 1 to position 4 in the genome (N4) and truncating the cytoplasmic tail (CT) of the VSV G protein from 29 to 1 amino acids (CT1) 12 . This rVSVN4CT1 vector was modified to maximally express HIV-1 gag from position 1 in the genome (rVSVN4CT1gag1) by positioning the gag gene immediately adjacent to the single strong 39 VSV transcription promoter. The rVSVN4CT1gag1 vector has demonstrated safety in mouse and NHP neurovirulence studies 12, 13 , and replication is restricted to the IM inoculation site and draining lymph node following vaccination of mice 14 . The rVSVN4CT1gag1 vector has demonstrated safety and immunogenicity in two phase I clinical trials (HVTN 090 and HVTN 087: http://clinicaltrials.gov/) and no post-vaccination viraemia was detected in urine, saliva, and blood of vaccine recipients. The rVSVN4CT1GP1 vector described here (Fig. 1a, N4 ) is analogous in design to that of the rVSVN4CT1gag1 vaccine and expresses ZEBOV GP from genome position 1. The other attenuated rVSV/ZEBOV *These authors contributed equally to this work.
vaccine described here (rVSVN1CT1GP3), expressing a truncated form of VSV G, was designed to be of intermediate attenuation between rVSVN4CT1GP1 and the first generation rVSV/ ZEBOVDG vaccine ( Fig. 1a, N1 ). Both attenuated rVSV/ZEBOV vectors express GP from the ZEBOV Mayinga strain, as do most other candidate ZEBOV vaccines currently under evaluation. Sequence homology between GPs from the new West African Makona strains analysed to date and the 1976 Mayinga strain is approximately 97%. Although this difference is not likely to affect the protective efficacy of the current ZEBOV vaccines against the heterologous West African strains, it is possible that small changes in sequence could lead to reduced efficacy of a vaccine 15 . It is well established that small variations in sequence and even single amino acid changes in sequence for other viruses including influenza, respiratory syncytial virus, polio, equine infectious anaemia virus, and SIV can reduce vaccine efficacy. Here we assessed the ability of our newly developed next-generation rVSV-based vaccines expressing ZEBOV Mayinga GP to protect against heterologous challenge with the new outbreak Makona strain of ZEBOV in cynomolgus monkeys. 
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Results from an in vitro growth kinetics study (Fig. 1b) indicate an approximate tenfold reduction in growth rate early in infection for rVSVN4CT1GP1 relative to rVSV/ZEBOVDG. Also noted during virus plaque assay were the larger more rapidly forming plaques generated by rVSV/ZEBOVDG compared to rVSVN4CT1GP1, with rVSVN1CT1GP3 showing intermediate growth and plaque size (Fig. 1c) .
We next tested if the further-attenuated rVSV/ZEBOV vaccines could provide NHPs with single-dose protection against challenge with ZEBOV isolated from the current outbreak in Guinea 16 . Groups of four cynomolgus macaques were inoculated intramuscularly with 2 3 10 7 plaque-forming units (PFU) of either rVSVN4CT1GP1 or rVSVN1CT1GP3; a group of two control macaques were unvaccinated (Fig. 1d, arrow heads) . None of the macaques showed any sign of illness or distress following vaccine administration. Consistent with the statistically significant growth differences between rVSV/ZEBOVDG and the more attenuated vectors seen during in vitro growth kinetics studies, levels of both attenuated vaccine viruses detected in the blood of vaccinated macaques (500 PFU per ml) were 10-to 50-fold lower than those detected for the more replication competent rVSV/ZEBOVDG 9 (Table 1, day 226) . The ZEBOV GP-specific humoral immune response was assessed for all animals before vaccination ( Fig. 2a, 228) and after vaccination (Fig. 2a, 218 and 0) by IgG capture ELISA and neutralizing antibody titres ( Table 1 , plaque 50% reduction neutralization test (PRNT) 50 ). Results showed neutralizing titres at terminal days for vaccinated cohorts and detectable circulating levels of anti-ZEBOV GP IgG for both vaccine cohorts after vaccination and before challenge with no detectable levels for the unvaccinated control animals ( Fig. 2a) . A cell-mediated immune response was also detected in all vaccinated animals by ZEBOV GP-specific interferon gamma (IFN-c) ELISpot assay 10 days after vaccination (Extended Data Fig. 1a and b) .
The eight vaccinated and two unvaccinated control macaques were challenged by intramuscular injection with 1,000 PFU of a low passage 100% 7U Makona strain stock of ZEBOV 16 28 days after the single injection vaccination (Fig. 1d, asterisk) . None of the animals vaccinated with either of the two further-attenuated rVSV/ZEBOV vectors showed any severe signs of illness following challenge with ZEBOV (Table 1) , whereas the two unvaccinated control macaques succumbed to disease on days 7 and 8 (Fig. 2b ). Circulating infectious ZEBOV was isolated from both of the unvaccinated control macaques on days 3 and 6 post challenge (Fig. 2c , blue) but no circulating infectious ZEBOV could be detected in any of the vaccinated animals. Examination of tissues by immunohistochemistry showed abundant ZEBOV antigen in tissues of the unvaccinated control animals (129 and 276) ( Fig. 3a-d) whereas ZEBOV antigen was not detected in tissues of the macaques vaccinated with rVSVN1CT1GP3 (1001100) or rVSVN4CT1GP1 (0807174) (Fig. 3e-h) .
Here we show protection against a new West African Makona strain of ZEBOV using a novel filovirus vaccine platform. The large reduction in vaccine-associated viraemia indicates a significant increase of in vivo attenuation for these next-generation rVSV/ZEBOV vaccine vectors, which should translate into greater safety and reduced adverse . e, f, Liver and spleen, respectively, with a lack of immunolabelling from N1 cohort animal 0910078. g, h, Liver and spleen, respectively, with a lack of immunolabelling from N4 cohort animal 0807174. 
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events in humans. Importantly, single-dose vaccination of NHPs with highly attenuated forms of rVSV expressing ZEBOV Mayinga GP provides complete protection from heterologous challenge with a highly virulent 7U ZEBOV isolated early during the current West African outbreak 16 . ZEBOV genome sequencing from cases later during the West Africa outbreak has revealed little drift in the GP gene 17, 18 , suggesting that this vaccine platform could also be efficacious against currently circulating ZEBOV. These findings pave the way for the identification and manufacture of safer, single-dose, high efficacy vaccine(s) to combat current and future filovirus outbreaks in Africa and their potential use as biological weapons.
